Laigo Bio

Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders.

Health and bio

Laigo Bio raised $19.7M in a Seed round announced March 23, 2026, according to BioXconomy.

Raise history

1. March 23, 2026
   Seed · $19.7M
   Source: BioXconomy

Related bio health companies

• SSharp$328K · Oct 1, 2026
• MM-BasedOct 1, 2026
• AAyna HealthOct 1, 2026
• VVytalYou$830K · Sep 30, 2026
• LLindera USSep 29, 2026
• OOrtet$500M · Sep 29, 2026
• AAptadir Therapeutics$45M · Sep 29, 2026
• GGoerSep 29, 2026

Every amount links to the page it came from. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/laigo-bio.